Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis [6]

New England Journal of Medicine

Volumn 345, Issue 3, 2001, Pages 225-

  Arzoo, K ^a   Sadeghi, S ^a   Pullarkat, V ^a  

^a LAC USC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; MORPHINE SULFATE; PAMIDRONIC ACID; PREDNISONE; VINBLASTINE;

BONE PAIN; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; HISTIOCYTOSIS X; HUMAN; LETTER; OSTEOLYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL;

ADULT; DIPHOSPHONATES; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; OSTEOLYSIS; PAIN;

EID: 0035913252     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200107193450318     Document Type: Letter

References (5)

1. Aredia: The once-monthly infusion for the treatment of bone metastases
2. Bisphosphonates in multiple myeloma
3. Bisphosphonates and breast carcinoma: Present and future
4. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
5. How can we improve the treatment of bone metastases further?